Trials / Terminated
TerminatedNCT00889733
Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer
A Phase I/II Trial of Intraperitoneal (IP) Cisplatin Combined With IV Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Their Initial Surgery Performed Following Neoadjuvant Intravenous Chemotherapy
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether intraperitoneal (IP) Cisplatin combined with intravenous (IV) Paclitaxel is well tolerated in women with epithelial ovarian cancer who have had neoadjuvant chemotherapy followed by initial debulking surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intraperitoneal (IP) Cisplatin | For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel. |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2009-07-01
- Completion
- 2009-12-01
- First posted
- 2009-04-29
- Last updated
- 2024-03-26
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00889733. Inclusion in this directory is not an endorsement.